Xiaojun Huang
Peking University People's Hospital · Nanfang Hospital, Southern Medical University · Peking Universiy Institute of Hematology,People's Hospital Pekiking Universiyy
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xiaojun Huang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:08 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07449286 · IFN-α in Relapse Prevention.Peking University People's Hospital · not yet recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
- N/ANCT07319793 · Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCTPeking University People's Hospital · not yet recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS) · principal investigator
- Ph1NCT07280494 · To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCTPeking University People's Hospital · recruiting · CD7+ T-ALL/LBL · principal investigator
- Ph2NCT07244406 · Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLHebei Senlang Biotechnology Inc., Ltd. · recruiting · B-ALL · principal investigator
- Ph3NCT06641414 · Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).Ascentage Pharma Group Inc. · recruiting · Higher-risk Myelodysplastic Syndrome · study chair
- Ph1NCT06444022 · hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell TransplantationNanfang Hospital, Southern Medical University · withdrawn · Acute Graft Versus Host Disease · study chair
- Ph3NCT06387069 · A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaHutchmed · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT06164288 · Safety and Efficacy Study of hAESCs Therapy for aGVHDShanghai iCELL Biotechnology Co., Ltd, Shanghai, China · completed · GVHD,Acute, aGVHD · principal investigator
- N/ANCT05921318 · Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCTPeking University People's Hospital · unknown · Hematologic Malignancy, Stem Cell Transplant Complications · principal investigator
- Ph1NCT05170568 · PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd. · unknown · CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · principal investigator
- Early Ph1NCT05013372 · CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's LymphomaPeking University People's Hospital · unknown · T-cell Non-Hodgkin's Lymphoma · principal investigator
- Ph1NCT04766840 · Donor-derived CAR-T Cells in the Treatment of AML PatientsBeijing Immunochina Medical Science & Technology Co., Ltd. · unknown · AML · principal investigator
- N/ANCT04298502 · The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in HumanPeking University People's Hospital · unknown · Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation · study chair
- Ph2NCT04126681 · A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseAscentage Pharma Group Inc. · completed · Chronic Myeloid Leukemia, Chronic Phase · principal investigator
- Ph2NCT03883100 · A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationAscentage Pharma Group Inc. · unknown · Chronic Myeloid Leukemia - Accelerated Phase · principal investigator
- Ph2NCT03883087 · A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationAscentage Pharma Group Inc. · unknown · Chronic Myeloid Leukemia, Chronic Phase · principal investigator
- N/ANCT03821987 · Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAAPeking University People's Hospital · unknown · Aplastic Anemia, Stem Cell Transplant Complications, Engraft Failure · principal investigator
- N/ANCT03764228 · Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell TransplantationPeking University People's Hospital · unknown · Acute-graft-versus-host Disease · principal investigator
- N/ANCT03759899 · hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell TransplantationPeking University People's Hospital · unknown · Leukemia · principal investigator
- N/ANCT03327285 · C-CAR011 Treatment in Subjects With ALL After HSCTPeking University People's Hospital · unknown · Acute Lymphoblastic Leukemia(ALL) · principal investigator
- N/ANCT03121079 · Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationPeking University People's Hospital · withdrawn · Interferon-A-2B, Relapse, Prevention · principal investigator
- N/ANCT02978274 · Natural Killer Cells Reconstitution Kinetics Post Haploidentical TransplantationPeking University People's Hospital · unknown · Natural Killer Cell Mediated Immunity · study chair
- Ph2NCT02659657 · Prophylaxis Roles of IL-2 Treatment on GVHD After TransplantationPeking University People's Hospital · unknown · Acute Graft-versus-host Disease · principal investigator
- N/ANCT01828619 · Study of New RIC Regimen of BuFlu in Older and/or Intolerable PatientsPeking University People's Hospital · unknown · Leukemia, Myelodysplastic Syndrome · principal investigator
- N/ANCT01793675 · Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic SyndromePeking University People's Hospital · completed · Advanced MDS Without Identical Sibling Donor · principal investigator
- N/ANCT01517347 · Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After TransplantationPeking University People's Hospital · terminated · Leukemia · principal investigator
- N/ANCT01455272 · New Therapy for Advanced Stage Leukemia After Stem Cell TransplantationPeking University People's Hospital · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:08 UTC. The ranking covers the 200 most relevant of 1414 PubMed records, and a shared surname and initials can bring in a namesake. All 1414 on PubMed
- 470 citationsRCR 33.7
- 414 citationsRCR 22.7
- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.J Clin Oncol · 2023381 citationsRCR 31.6
- 318 citationsRCR 22.2
- 300 citationsRCR 13.7
- Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.N Engl J Med · 2024298 citationsRCR 34.6
- Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.Lancet Gastroenterol Hepatol · 2021230 citationsRCR 17.0
- 193 citationsRCR 16.8
- 192 citationsRCR 11.8
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.Clin Cancer Res · 2022191 citationsRCR 12.5